Distress Tolerance and Buprenorphine (TRUST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01556087
Recruitment Status : Completed
First Posted : March 16, 2012
Last Update Posted : September 10, 2015
Information provided by (Responsible Party):
Michael Stein, MD, Butler Hospital

Brief Summary:
The investigators propose that inability to tolerate the distress of opioid withdrawal and the negative affect associated with early abstinence are key factors in early illicit opioid lapse and subsequent buprenorphine treatment drop-out. Our intervention aimed at increasing distress tolerance is designed to increase treatment adherence.

Condition or disease Intervention/treatment Phase
Opioid Dependence Behavioral: Distress Tolerance Behavioral: Health Education Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 59 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Distress Tolerance and Reducing Early Relapse in Buprenorphine Patients
Study Start Date : March 2012
Actual Primary Completion Date : February 2014
Actual Study Completion Date : August 2015

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Distress Tolerance
7 sessions aimed at increasing distress tolerance skills
Behavioral: Distress Tolerance
7 individual sessions aimed at increasing distress tolerance skills
Placebo Comparator: Health Education
7 didactic health education sessions
Behavioral: Health Education
7 individual sessions with didactic health education information

Primary Outcome Measures :
  1. the Client Satisfaction Questionnaire-8 [ Time Frame: 4 months ]
    assess patient satisfaction with services

  2. buprenorphine treatment adherence [ Time Frame: 4 months ]
    adherence to buprenorphine treatment, which includes opioid use and risk behaviors, will be assessed

Secondary Outcome Measures :
  1. distress tolerance persistence [ Time Frame: 4 months ]
    mechanisms hypothesized to mediate the relationship between DT treatment and improved buprenorphine outcomes will be assessed

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • initiating buprenorphine treatment (which requires meeting current criteria for a DSM-IV diagnosis of opioid dependence)
  • plan to remain on buprenorphine for at least three months
  • age between 18 and 65 years
  • if female of childbearing potential -- must be using adequate contraception (an intrauterine device, oral contraceptive, depot contraceptive, a barrier method "every time," or hysterectomy) as assessed by the study physician
  • has at least two persons they regularly contact and can provide contact information for them
  • speaks English sufficiently to understand instructions and assessments.

Exclusion Criteria:

  • current methadone maintenance treatment program participation
  • medically necessary prescription opioid treatment (e.g., for chronic pain)
  • current criteria for a DSM-IV diagnosis of substance dependence for sedative/hypnotic drugs, alcohol, stimulants, cocaine, inhalants, hallucinogens
  • a diagnosis of organic brain disorder, bipolar disorder, schizophrenia, schizo-affective, schizophreniform, or paranoid disorder, or major depression (subjects who meet criteria for "substance-induced mood disorder," or dysthymia only will not be excluded)
  • current suicidality on the Modified Scale for Suicidal Ideation
  • use of daily psychotropic, antidepressant, or anxiolytic medication
  • evidence of neuropsychological dysfunction as assessed by the study physician with confirmation with the Folstein Mini-Mental Status Examination
  • anticipated major painful event (significant surgical procedure) in the coming 6 months
  • probation/parole requirements that might interfere with protocol participation
  • history of allergic reaction to buprenorphine or naloxone.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01556087

United States, Rhode Island
Butler Hospital
Providence, Rhode Island, United States, 02906
Sponsors and Collaborators
Butler Hospital

Responsible Party: Michael Stein, MD, Principal Investigator, Butler Hospital Identifier: NCT01556087     History of Changes
Other Study ID Numbers: DA032767
First Posted: March 16, 2012    Key Record Dates
Last Update Posted: September 10, 2015
Last Verified: September 2015

Keywords provided by Michael Stein, MD, Butler Hospital:
distress tolerance

Additional relevant MeSH terms:
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists